Originally posted on “Value innovation in medical and life sciences” ; August 12th, 2009
Thanks to Silja Chouquet (@whydotpharma) and Andrew Spong (@andrewspong), â€œtwittersâ€ on the internet interested in social media in health care and pharma, had a first Tweet up on this issue at the twitter site #hcsmeu, friday august 7th .
In a first reflection on this virtual gathering, (http://bit.ly/1m61I3) Andrew Spong, already noted the presence of people from France, Spain, Italy, Germany, Portugal, Switzerland, Turkey and the UK. Â Specifically too, the early rise of people from the US to join in. They gathered through the twitter site to discuss first issues, put forward by Silja and Andrew:
- Tell us about the use of social media in health care in your country,
- What are the most important differences between the use of social media EU vs. US?
- What is the key driver of the adoption of hcsm (health care social media) Â in your country? Patient advocacy, health care professionals (hcp) bloggers, or national health systems?
So no lack of interests, as can also be seen at #hcsm.
(Andrew produced a Gdoc by with the raw tweets: http://tr.im/w90C )
Well, what came forward?
Concerning the difference of the social media situation over EU countries. These do not seem to be large. Rather, there is a resemblance in all EU countries in social media just beginning to evolve. In no country according to the participants, thereâ€™s a fierce development or exploitation of social media. There are nice examples and serious attempts, but they seem to be in a state of â€œtrying toâ€.
Some statements specifically: In Spain for instance, recent research shows interest by pharmaceutical companies to use media as a way to relate to stakeholders, but are reluctant due to local regulation. In the top 100 sites in Spain, visited by Spaniards looking for health information, none stems from a Pharma company. SuchÂ is said to apply for Germany too. One discerns a positive development, also from health care insurers, but the mindset is still â€˜system madeâ€™. Traffic from German healthcare seeker on the internet land for the most part on health care start ups with social media applications or health care portals with communities and forums. Such could be said to be the case as well in the Netherlands. Some sites open up to patients/consumers and these are mostly run by specific patient associations. For Germany and the Netherlands applies that social media and Rx do not go together.
As for the UK, it was mentioned that there is a local NHS on Twitter. Furthermore, that one is putting together in the UK a working party to discuss digital media and the use of social media in pharma. Overall, it is noted that information in social media is more shouting at people than interacting with them. Isnâ€™t that typical for the evolving phase SM is in?
But there is an interesting example in France of sponsoring the breast cancer community by @roche. Such sponsoring examples might be found in the Netherlands too, although pharma companies are expected to publish their sponsorship relations to patient associations, as is the case elsewhere in the EU too, as I presume.
On the differences between the US and EU on the use of social media, it was generally acknowledged that the allowance of DTC in the US and the prohibition of direct consumer adds in the EU concerning prescriptions, is the most striking one. But the question remained whether that is the main reason for the slow development of the use of SM in the EU. Wouldnâ€™t the use of different languages have an impact â€“ Imagine French, Spanish, Italian, German, English, etc..? Others thought that the attitude of EU Pharma companies differs from across the ocean in the US: these are perceived to be more aggressive than in the EU and more apt for going on until one gets what one wants.. But then again, regulatory arrangements, promotion and communication rules for pharma differ over EU countries and national authorities are keen to maintain them. Â Well for that matter, associations were made as to â€œUSâ€ and â€œEUâ€ attitudes as for â€œdoersâ€ and â€œthinkersâ€, or as for aggressive or academic â€“ I think that is one issue to further explore as for its meaning â€“ if it be no biased remark. Anyway, attitude in the sense of â€œiron-willedâ€ advocacy for social media is seen as a prerequisite to pursue the innovation and to champion social media as an authentic means of improving pharmaâ€™s image.
And, in my view more importantly, though there is no DTC in the EU, and altho
Another issue of importance to influence the emergence of social media in the EU, undoubtedly, is said to be the differences in reimbursement schemes, which boils down to the question: when social media are to be in the realm of free services: who is going to pay. When prices for pharmaceuticals are under harsh pressure, where are the extras to be found to generate budgets in pharma for social media development. Yes, sales forces are shrinking, but that is not with the intention to pay for social media, is it? One specific remark to that was given: pharmaâ€™s attitude would be still too relational to be transactional, as is needed in social media.
Concerning the question for the key drivers to the adoption and use of social media, a lot of the same issues as mentioned before were forwarded here too.
Attitude is relevant, and again context of rules, regulations, reimbursement, and specifically the separation of community segregation between health care, patients/consumer communities and health care, Rx professionals. In this sense, pharma programs for compliance online are said to be questioned by the European Commission! Actually I, myself do not see those communities integrate, due to the difference in perspectives, but once care itself is at stake, and not just Rx, there could be a chance to relate health care professionals through social media to patients. There must be some good examples already!
And indeed, patient associations are forwarded as the drivers to social media development. They will have transparency, relevance, reciprocity, authenticity, commitment â€˜baked inâ€™ their strives, as relevant issues for success in this.
Interesting enough, aspects of pharma companiesâ€™ organisations came forward as probable inhibitors to their development in using social media: the issue of change, and management of change. Also, the attitude as how to adapt to given contexts or as to be challenged by opportunities. Adhesion of top management plays a role, one remarks, but also the issue of linking social media to EU strategies of pharma, not just to affiliatesâ€™ tactics locally.
In my personal conclusion: we are just beginning to discuss and use the potential of possibilities and opportunities generated by social media in the EU. But one striking issue seems relevant to mention here. I would make a serious distinction between the use of social media in the pursue of care for health, and the use of these channels for pharma promotionâ€¦The latter seems just one bridge too far to pharma in the EU. But still, when pharma is able to collaborate with other parties to the use of social media in health care, new images of pharma and positions in health care communities lay ahead. Probably things pharma could need. But indeed, thatâ€™s quite a change!
Every Friday, one will have a next tweet up on #hcsmeu, around noon GMT+1
Rob Halkes (@rohal)
Comment by Miguel A. Tovar at August 12th, 2009 at 10:52 | #1
Comment by Silja Chouquet, at August 12th, 2009 at 12:03 | #2
Comment by Andrew Spong at August 13th, 2009 at 07:47 | #3